Everyone Already Knows Everything About Megacaps … But Not These Stocks
Stocks like Apple and Amazon are a like an open book everyone has already read. That’s why I get an edge researching this type of stock.
Stocks like Apple and Amazon are a like an open book everyone has already read. That’s why I get an edge researching this type of stock.
We added to three holdings and laid out what we’re watching for several others.
* The markets, that is…
From the ridiculous:
Dr Frankenstein: Now that brain that you gave me, was it Hans Del Brooks?
Igor: No.
Dr. Frankenstein: Would you mind telling me whose brain I did put in?
Igor: Abby someone.
Dr. Franksenstein: Abby, who?
Igor: Abby Normal – I am almost sure that was the name.
Dr. Frankenstein: Are you saying I put an abnormal brain into a 7 1/2 foot long, 54 inch wide gorilla?
– Young Frankenstein Abby normal scene – YouTube
To the sublime:
“Something is rotten in Denmark.”
– Grandma Koufax
The market’s (daily and intraday) volatility and absence of memory from day to day suggests, to me, that something is awry. At the very least, the inconsistency and lack of predictability of the market (again from day to day), feels like the markets are becoming more casino-like.
Amazon ($AMZN), up $5+ yesterday, down $5+ today. Or Walmart ($WMT) -$11 (the consumer is faltering as I suggested in my Diary this week — and wasn’t the investment case that WMT is positioned ideally for AI advances?). And, of course, the daily gyrations of memory and chip stocks.
This backdrop is great for opportunistic traders, not so great for the buy-and-hold crowd.
I have been wrong about the markets, but I have little interest in gambling with my Limited Partners’ hard earned capital — even if there are continued opportunity costs — as I feel the wheels might fall off of the U.S. stock market at any time.
Position: None
Comp sales data favor Costco, while TJX shares enter oversold territory.
Heading into the holiday shopping season, we continue to see the company benefitting from cash-strapped consumers.
I reduced three biotech winners, and not because I think they are going down.
It would be a mistake to give full credit to the implied potential or to rule out Broadcom.
The market is under pressure but buying opportunities are slowly developing; here’s how I’m trying to time an entry.
Amid ‘troubling’ market action Monday, here’s what to know about one of my top small-cap plays.
What’s next for the U.S. and Iran, S&P 500 targets, retail earnings and other headlines moving the market this morning.